C4 Therapeutics Stock Nears Breakout Zone as Cancer-Drug Catalysts Put CCCC Back on Watch
C4 Therapeutics shares traded at $3.74 before the Nasdaq open on May 28, holding gains after a 7.16% rise the prior session. The move comes as investors await cemsidomide updates at ASCO and EHA meetings. C4 reported $268.3 million in cash at March 31 and a narrowed Q1 net loss. The company expanded its Roche partnership in April, securing a $20 million upfront payment.